Skip to main content

Abstracts

2020

Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-Small-Cell-Lung Cancer in Greece

Gourzoulidis G, Zisimopoulou O, Boubouchairopoulou N, Michailidi C, Almond C, Tzanetakos C, et al. Value in Health. 2020;23:S442. https://doi.org/10.1016/j.jval.2020.08.244

2019

Cost-minimization Analysis of Damoctocog Alfa Pegol in severe Hemophilia A in Greece

Vellopoulou K, Georgilis A, Byrne A, Gray E, De Meyer N, Kourlaba G Value in Health. 2019;22:S848. https://doi.org/10.1016/j.jval.2019.09.2371

2019

Cost-effectiveness analysis of Tofacitinib for the treatment of moderate to severe active uclerative colitis in Greece

Vellopoulou K, Stefanou G, Tzanetakos C, Boubouchairopoulou N, Nakou M, Kourlaba G. Value in Health. 2019;22:S619-S20. https://doi.org/10.1016/j.jval.2019.09.1142

2019

Budget Impact Analysis of Damoctocog Alfa Pegol in Severe Hemophilia A in Greece

Vellopoulou K, Georgilis A, Byrne A, Gray E, De Meyer N, Kourlaba G. Value in Health. 2019;22:S844.

2019

Real-World Data of Nivolumab in Non Small Cell Lung Cancer patients in Greece

Kourlaba G, Kokkotou E, Papaspiliou A, Stefanou G, Stournara L, Syrigos K. Value in Health. 2019;22:S435-S6. https://doi.org/10.1016/j.jval.2019.09.202

2019

Budget Impact Analysis of a Biosynthetic MESH for abdominal Wall Hernia repair in Complex Hernias in Greece

Vellopoulou K, Apostolidis S, Chatzimavroudis G, Chrisoheris P, Christodoulidis G, Ntatsis K, et al. Value in Health. 2019;22:S673. https://doi.org/10.1016/j.jval.2019.09.1436

2019

End-of-LIFE Cost for Lung Cancer Patients in Greece: A hospital-based retrospective study

Kourlaba G, Kokkotou E, Papaspiliou A, Stefanou G, Stournara L, Syrigos K. Value in Health. 2019;22:S476. https://doi.org/10.1016/j.jval.2019.09.405

2019

Does a standard Willingness-to-pay thereshold exist in Greece?

Tzanetakos C, Stefanou G, Gourzoulidis G. Value in Health. 2019;22:S772-S3. https://doi.org/10.1016/j.jval.2019.09.1963

2022

COST-UTILITY ANALYSIS OF PEGASPARGASE FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN GREECE

Gourzoulidis G, Koulentaki M, Kattamis A, Bouzani M, Giatra C, Chotzagiannoglou V, Beletsi A, Kourlaba G, Econcare LP, Athens, A, Greece,  First Department of Pediatrics, National and Kapodistrian University of Athens, ’Aghia Sophia’ Children’s Hospital, Athens, Greece,  Hematology and Lymphoma Department, Evangelismos General Hospital, Athens, Greece,  SERVIER HELLAS Pharmaceuticals LTD, Athens, A1, Greece Value in Health. 2022;01:S101. 

2022

BUDGET IMPACT ANALYSIS OF PEGASPARGASE FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN GREECE

Gourzoulidis G, Koulentaki M, Kattamis A, Bouzani M, Giatra C, Chotzagiannoglou V, Beletsi A, Kourlaba G Econcare LP, Athens, A1, Greece,  First Department of Pediatrics, National and Kapodistrian University of Athens, ’Aghia Sophia’ Children’s Hospital, Athens, Greece,  Hematology and Lymphoma Department, Evangelismos General Hospital, Athens, Greece,  SERVIER HELLAS Pharmaceuticals LTD, Athens, A1, Greece. 2022;01:S48.